6 results
The primary objective of this study is to estimate the incidence of ocular adverse events in patients with CNV secondary to AMD who receive an individualized treatment with ranibizumab 0,3 mg.
The objective is to analyze whether a difference in reservecapacity is present between short-term and long-term PD patients. In case the reservecapacity of the peritoneum is significantly lower in the long-term compared to short-term PD patients, a…
Het objectives of the study are to demonstrate that combination therapy of Lucentis and Visudyne is not inferior in effectivity and safety to monotherapy with Lucentis and to investigate whether less Lucentis injections in combination therapy with…
Evaluating the long term safety and tolerability of ranibizumab treatment of AMD patients.
Primary objectiveTo assess the efficacy of intravitreally (ITV) administered VEGF Trap-Eye compared to ranibizumab (in a non-inferiority paradigm) in preventing moderate vision loss in subjects with all subtypes of neovascular AMD Secondary…
Main study:1. Does blockade of the angiotensin II AT1-receptor improve the insulin-induced microvascular effects in hypertensive patients.2. Does blockade of the angiotensin II AT1-receptor impair the insulin-induced mi-crovascular effects in…